Onco Wiki - Drogas

Rituximab

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDDRUG-RITUXIMAB
TipoFármaco
Aliaces
La madre de TheraRiabni (biosimilar)RituxanRuxiencia (biosimilar)Truxima (biosimilar)Ритуксимаб
Situaciónreviewed 2026-04-26 | pending_clinical_signoff
EnfermedadesDIS-B-ALL DIS-BURKITT DIS-CLL DIS-DLBCL-NOS DIS-FL DIS-HCL DIS-HCV-MZL DIS-HGBL-DH DIS-MCL DIS-NLPBL DIS-NODAL-MZL DIS-PCNSL DIS-PMBCL DIS-PTLD DIS-SPLENIC-MZL DIS-T-ALL DIS-WM
FuentesSRC-ESMO-MZL-2024 SRC-NCCN-BCELL-2025

Datos sobre drogas

Clasemonoclonal_antibody — anti-CD20 chimeric IgG1κ
MecanismoChimeric (mouse-human) monoclonal antibody binding the CD20 antigen on B lymphocytes (pre-B through mature B; sparing pro-B and plasma cells). Depletes CD20+ B cells via three mechanisms: complement-dependent cytotoxicity (CDC, dominant in CLL), antibody-dependent cellular cytotoxicity (ADCC, dominant in lymphoma), and direct apoptosis via CD20 cross-linking. Recovery of normal B cells takes 6-12 months after the last dose.
Dosificación típicaR-CHOP / R-CVP / R-Bendamustine (DLBCL, FL): 375 mg/m² IV day 1 of each 21- or 28-day cycle × 6-8 cycles. R-monotherapy / FL maintenance: 375 mg/m² IV every 8-12 weeks × 2 years (PRIMA / RESORT schedules). CLL (R-FC, R-Ben): 375 mg/m² IV cycle 1 day 1, then 500 mg/m² IV day 1 cycles 2-6. SC formulation (FL, DLBCL): 1400 mg fixed-dose SC over ~5 minutes from cycle 2 onward (after first IV dose for tolerability).
Ucrania registradaCierto
NSZU reembolsadoCierto
Ucrania verificada por última vez2026-04-27

Advertencias

Notas

Foundation anti-CD20 therapy in B-cell lymphomas. Premedication (acetaminophen + diphenhydramine ± methylprednisolone) before each infusion; first-dose infusion rate escalation per protocol (50 mg/h start, doubled q30min to max 400 mg/h). HBV screening (HBsAg + anti-HBc + anti-HBs) is mandatory before first dose; entecavir or tenofovir prophylaxis throughout therapy and ≥12 months post for any HBV-positive serology. SC formulation reduces administration time from 4-6 h to 5-7 minutes and is preferred from cycle 2 onward in FL / DLBCL. For HCV-MZL, reserved for cases not responding to antiviral therapy alone, or aggressive phenotype where immediate cytoreduction is indicated. Biosimilars are clinically interchangeable in UA per НСЗУ guidance.

Utilizado por

Contraindications

Esquema terapéutico